Objective To investigate the effects of mifepristone on expression of estrogen receptor (ER) and progeserone receptor (PR) in cultured human eutopic and ectopic endometria. Methods Endometrial (n=22) and endometriotic (n=12) tissues，obtained from patients with endometriosis, were cultured with and without mifepristone (1×10-6 mol/L，1×10-4 mol/L) for 7～10 days. The expressions of ER, PR were determined by semi-quantitative immunocytochemistry method. Thirteen normal endometrial samples served as controls. Results The expressions of ER and PR in normal and eutopic endometrial cells showed the same cyclic pattern. The only difference was the significantly higher PR glandular content in eutopic endometria of endometriosis patients ,as compared with normal controls ［histochemistry score (H-score) 2.77±0.32 Vs 2.20±0.26 P<0.05］. On the contrary, the ER, PR expressions in ectopic endometrial cells were significantly lower only during the proliferative phase (ER: gland 0.65～2.17 Vs 1.50～3.23, stroma 0.45～1.03 Vs 0.80～1.96; PR: gland 0.55～1.77 Vs 1.55～3.34, stroma 0.40～1.27 Vs 0.98～2.50; P<0.05～0.01); significantly higher only during the late secretory phase (ER: gland 3.27±0.31 Vs 0.28±0.11, stroma 1.87±0.31 Vs 0.26±0.15; PR: gland 3.33±0.23 Vs 0.36±0.23) as compared with those of eutopic endometria.10-6～10-4 mol/L of mifepristone significantly suppressed the expressions of ER, PR in both eutopic and ectopic endometrial cells of endometriosis patients (P<0.01) in a dose-dependent manner. Conclusions Expression of ER, PR of endometriotic cells differed significantly from that of endometrial cells of patients with or without endometriosis. The down-regulatory effect on ER and PR may be one of the therapeutic mechanism of mifepristone on endometriosis.%目的 探讨子宫内膜异位症(内异症)的异位与在位内膜雌、孕激素受体(ER、PR)含量，及米非司酮对其影响。方法 采用免疫细胞化学法，分析22例内异症患者的在位内膜细胞和其中12例患者的异位内膜细胞体外培养后的ER、PR含量，观察不同浓度米非司酮(1×10-6 mol/L和1×10-4 mol/L)作用后的变化，并以13例正常子宫内膜作对照。结果 内异症的在位内膜ER、PR含量呈明显周期性变化，分泌早期腺体PR含量显著高于正常子宫内膜［组织化学评分(下同)为2.77±0.32与2.20±0.26，P<0.05］。内异症的异位内膜，增殖期ER(腺体0.65～2.17，间质0.45～1.03)、PR含量(腺体0.55～1.77，间质0.40～1.27)显著低于在位内膜(ER：腺体1.50～3.23，间质0.80～1.96；PR：腺体1.55～3.34，间质0.98～2.50，P<0.05～0.01)；分泌早期无差异；分泌晚期腺体ER含量(3.27±0.31)、PR含量(3.33±0.23)与间质ER含量(1.87±0.31)显著高于在位内膜(分别为0.28±0.11、0.36±0.23和0.26±0.15，P<0.01)，而间质PR含量无差异。米非司酮可明显降低内异症的异位和在位内膜ER、PR含量(P<0.01)，且米非司酮浓度越高，ER、PR含量降低越明显。结论 内异症的异位和在位内膜ER、PR含量明显不同，米非司酮可下调异位和在位内膜ER、PR的含量。
展开▼
